S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Pulmatrix Stock Forecast, Price & News

-0.03 (-3.85%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
205,500 shs
Average Volume
1.17 million shs
Market Capitalization
$36.56 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

Pulmatrix logo

About Pulmatrix

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$12.63 million
Book Value
$0.80 per share


Net Income
$-19.31 million
Net Margins
Pretax Margin




Free Float
Market Cap
$36.56 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.78 out of 5 stars

Medical Sector

838th out of 1,391 stocks

Pharmaceutical Preparations Industry

402nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

Is Pulmatrix a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pulmatrix stock.
View analyst ratings for Pulmatrix
or view top-rated stocks.

How has Pulmatrix's stock been impacted by COVID-19 (Coronavirus)?

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PULM shares have decreased by 52.9% and is now trading at $0.65.
View which stocks have been most impacted by COVID-19

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Pulmatrix

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) posted its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.08. Pulmatrix had a negative trailing twelve-month return on equity of 34.73% and a negative net margin of 283.61%.
View Pulmatrix's earnings history

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix's stock reverse split on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PULM?

1 brokerages have issued 12-month target prices for Pulmatrix's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Pulmatrix's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price.
View analysts' price targets for Pulmatrix
or view top-rated stocks among Wall Street analysts.

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the following people:
  • Teofilo Raad, President, Chief Executive Officer & Director
  • Michelle Siegert, Secretary, Treasurer & Vice President-Finance
  • Aidan Curran, Head-Research
  • Rusty Clayton, Clinical Programs Medical Director

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.79%), BlackRock Inc. (2.22%), Geode Capital Management LLC (0.90%), Morgan Stanley (0.21%), First Republic Investment Management Inc. (0.09%) and Citadel Advisors LLC (0.08%).
View institutional ownership trends for Pulmatrix

Which institutional investors are selling Pulmatrix stock?

PULM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, and BlackRock Inc..
View insider buying and selling activity for Pulmatrix
or view top insider-selling stocks.

Which institutional investors are buying Pulmatrix stock?

PULM stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, First Republic Investment Management Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Pulmatrix
or or view top insider-buying stocks.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $0.65.

How much money does Pulmatrix make?

Pulmatrix has a market capitalization of $36.56 million and generates $12.63 million in revenue each year. The biotechnology company earns $-19.31 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Pulmatrix have?

Pulmatrix employs 21 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is www.pulmatrix.com.

Where are Pulmatrix's headquarters?

Pulmatrix is headquartered at 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 357-2333, via email at [email protected], or via fax at 707-525-9906.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.